Table 3.
Treatment outcomes after chemotherapy
| Variable | CR rate | Response rate (CR + PR) |
|---|---|---|
| 1st line chemotherapy regimen (n = 90) | ||
| Chlorambucil (n = 43) | 7 (16.3) | 29 (67.5) |
| Fludarabine (n = 13) | 1 (7.7) | 7 (63.6) |
| FCR (n = 4) | 1 (25) | 3 (75.0) |
| FC (n = 20) | 1 (35.0) | 18 (90) |
| CVP (n = 4) | 0 | 3 (75.0) |
| RF (n = 1) | 0 | 1 (100) |
| Others (hydroxyurea, VP, Cy + PD) (n = 5) | 0 | 2 (40.0) |
| Cytogenetics (n = 73)a | p = 0.011 | |
| IgH rearrangement (n = 6) | 4 (66.7) | |
| Normal karyotype/others (n = 62) | 11 (17.7) | |
| Del(11q)/del(17)/CK (n = 5) | 0 |
Values are presented as number (%).
CR, complete remission; PR, partial remission; FCR, fludarabine, cyclophosphamide, and rituximab; FC, fludarabine and cyclophosphamide; CVP, cyclophosphadmie, vincristine and prednisolone; RF, rituximab and fludarabine; VP, vincristine and prednisolone; Cy + PD, cyclophosphadmie and prednisolone; IgH, immunoglobulin heavy locus; CK, complex karyotype.
a
At the initiation of first-line chemotherapy.